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ABSTRACT
Dyslipidemia is a well-established modifiable cardiovascular risk. Although statins can reduce LDLc by
50–60%, less than 20% of patients with high risk of CVD achieve LDL targets. The aim of this system-
atic review is to evaluate the effect of the nutraceutical, bergamot (Citrus bergamia), on lipid parame-
ters in humans. PubMed, Embase, Cochrane Library, and Google Scholar databases were searched for
interventional and observational studies investigating the effect of bergamot on lipid profile in
humans. This systematic review retrieved a total of 442 studies of which 12 articles fulfilled the eligi-
bility criteria and were included in the qualitative synthesis. Based on data, 75% of studies showed a
significant decrease in total cholesterol, triglycerides and LDLc. The decrease in total cholesterol var-
ied from 12.3% to 31.3%, from 7.6% to 40.8% in LDLc and from 11.5% to 39.5% in triglycerides.
Eight trials reported HDLc increase after intervention with bergamot. Overall, a dose-dependent and
possible synergistic effect when administering with statins can be deducted from these trials. It is
essential to point out that studies had heterogeneous designs and scientific quality of studies was
quite limited. Promising findings reveal an alternative therapeutic option in dyslipidemia manage-
ment with bergamot supplementation, especially in subjects with statins intolerance.
KEYWORDS
Bergamot; Citrus bergamia;
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cholesterol; triglycerides
Introduction
Dyslipidemia is a well-established modifiable cardiovascular
risk factor and its treatment is an essential aim in the pre-
vention of cardiovascular diseases (CVD), which represent
the leading cause of death and use of health service in devel-
oped countries (Bea et al. 2017). Current guidelines high-
lights lifestyle intervention as a key issue in the management
of patients with hyperlipidemia, but it is often scarce to control
the lipid profile (Grundy et al. 2018). Current lipid-lowering
therapies, mainly statins with or without ezetimibe, can reduce
LDL cholesterol by 50–60% and they are proven to reduce pri-
mary and secondary cardiovascular endpoints (Masana et al.
2017). However, less than 20% of patients with high risk of
CVD achieve LDL targets and up to 60% of patients refer to
some statin intolerance or side effects related to this treatment
(Masana et al. 2017; Zhang et al. 2013). This constitutes the
main reason for statin discontinuation and poor adherence to
treatment that remains a significant problem in dyslipidemia
management (Banach et al. 2016). The increasing need to find
a nonpharmacological alternative, in particular for patients
with moderate hypercholesterolemia, low cardiovascular risk or
intolerance to traditional pharmacological treatment, has led to
test many phytochemicals as nutraceuticals that have shown
lipid-lowering properties (Johnston et al. 2017). Nutraceuticals
are food components that may be used as therapeutic agents
due to their beneficial effects on health (Kalra 2003).
Recent studies have shown that Bergamot (Citrus berga-
mia) juice and its flavonoids were able to reduce serum lev-
els of lipids, even improving atherosclerosis through
modulating enzymatic activities, antioxidation, antiinflam-
matory mechanisms and inhibition of monocyte activation
and proliferation (Ferlazzo et al. 2016; Benavente-Garcıa and
Castillo 2008; Ferlazzo et al. 2015; Li et al. 2016). Bergamot
is an endemic plant growing in the Calabrian region of
Southern Italy with a unique profile of flavonoids and glyco-
sides present in its juice and albedo, such as neoeriocitrin,
neohesperidin, naringin, rutin, neodesmin, rhoifolin and
poncirin (Gliozzi et al. 2013). Bergamot differs from other
citrus fruits, not only for the nutritional composition, but
also for the particularly high content of flavonoids (Nogata
et al. 2006; Dugo et al. 2005). Some of these flavonoids,
such as naringin and its aglycone naringenin, have already
been shown to have an antiatherogenic effect on animal
models, while neoeriocitrin and rutin have been found to
inhibit LDL oxidation (Yu et al. 2005). Besides, bergamot
juice is rich in 3-hidroxy-3-methylglutaryl neohesperidosides
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of hesperetin (brutieridine) and naringenin (melitidine) with
the ability to inhibit HMG-CoA reductase (Di Donna et al.
2009). These compounds are likely to contribute to the sub-
stantial hypolipidemic effects that bergamot juice has demon-
strated in several animal studies (Mollace et al. 2008; Miceli
et al. 2007). However, to date, there are few human studies
that have evaluated the effect of bergamot in adults with dysli-
pidemia. Thus, the aim of this systematic review is to evaluate
the effect of bergamot, as isolated component or as part of a
nutraceutical product, in lipid profile (total cholesterol, LDL
cholesterol, triglycerides, and HDL cholesterol) in humans.
Methods
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews (Liberati et al. 2009).
Prisma checklist is available in Supplemental Table 1.
Search strategy and study selection
A systematic search of the relevant literature was performed
with the use of PubMed, Embase, Cochrane Library, and
Google Scholar in order to identify interventional studies
investigating the effect of bergamot on lipid profile in
humans. If available, we also included systematic reviews,
meta-analysis and clinical guidelines. References of included
studies and reviews were manually checked for additional
studies. The structured search strategies used the combin-
ation of bergamot and different outcomes related to lipid
profile: [Bergamot OR Citrus bergamia OR Nutraceuticals]
AND [Cholesterol OR Dyslipidemia OR Hyperlipidemia OR
Cardiovascular disease OR Cardiovascular risk OR Lipids
OR Lipoprotein OR Low-density lipoprotein OR High-
density lipoprotein OR Lipid-lowering drugs OR
Triglycerides]. Articles retrieved were then included or
excluded based on the following criteria. Inclusion criteria
included: (a) articles published in a peer-reviewed journal;
(b) cross-sectional, cohort, and interventional studies; (c)
studies conducted in both children and adults; (d) studies
conducted in healthy humans, or those with metabolic
impairment (overweight, obese, hypercholesterolemic, prehy-
pertensive, hypertensive, or with type 2 diabetes) or any
other disease. Exclusion criteria involved: (a) case studies;
(b) letters, commentaries, conference papers, narrative
reviews; (c) studies not conducted in humans. The search
was limited to literature presented in English.
Outcome measures
Outcomes of interest were changes in total cholesterol, LDL
cholesterol, HDL cholesterol, and triglycerides.
Quality measures
The quality of each included trial was assessed based on the
previously validated methodology developed by Kmet et al.
(2004). The methodology was derived from a checklist for
assessing the quality of quantitative studies, which included
the following criteria: (1) Question, objective sufficiently
described?; (2) Study design evident and appropriate?; (3)
Method of subject, comparison group selection or source of
information, input variables described and appropriate?; (4)
Subject and comparison group (if applicable) characteristics
sufficiently described?; (5) If interventional and random
allocation was possible, was it reported?; (6) If interventional
and blinding of investigators was possible, was it reported?;
(7) If interventional and blinding of subjects was possible,
was it reported?; (8) Outcome and (if applicable) exposure
measure(s) well defined and robust to measurement, mis-
classification bias? Means of assessment reported?; (9)
Sample size appropriate?; (10) Analytic methods described,
justified and appropriate?; (11) Some estimate of variance is
reported for the main results?; (12) Controlling for con-
founding?; (13) Results reported in sufficient detail?; (14)
Conclusion supported by the results?. Each question can be
answered with “yes,” “partial,” “no,” or “not applicable.”
Scoring process was done according to the following for-
mula: ((number of “yes” x2) þ (number of “partial” x1)/
(total possible sum (28) – (number of “not applicable” x2)).
The score ranged from 0 to 1; thus, the closer the value is
to 1, the higher is the quality of the trial. Quality assessment
of each trial was performed by three different researches
(ILM, JGG and RMG). Two researchers performed the qual-
ity checklist of each trial; if a discordance was found (differ-
ence mean score more than 0.1 points), a third review by
the remaining researcher was performed.
Results
Study selection
The systematic search retrieved a total of 442 studies of
which 361 were identified in PubMed and 61 in Cochrane,
Google Scholar and Embase. After removing 18 duplicated
articles, we screened 404 manuscripts of which 293 were
excluded because of they did not meet the requirement of
eligibility criteria. We made full-text review of 118, exclud-
ing 106 articles for different reasons: most excluded articles
did not include bergamot as active principle within the
intervention, they were in vitro studies or developed in ani-
mal models (n¼ 90), they were reviews (n¼ 15) and we
were unable to access to one full-text manuscript (n¼ 1).
Finally, 12 articles (10 intervention studies and 2 observa-
tional studies) fulfilled the eligibility criteria and were
included in qualitative synthesis (Figure 1).
Participants and main study characteristics
A detailed description of the included studies can be found
in Table 1. The 12 studies included a total of 870 adults’
participants (aged 27–77 years). There was quite heterogen-
eity in clinical characteristics of populations. In summary,
two trials recruited subjects with overweight or obesity and
other cardiovascular risk factors (Dahlberg et al. 2017) or
metabolic syndrome (Di Folco et al. 2018), four trials
included subjects with mixed hyperlipidemia (Gliozzi et al.
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2013; Mollace et al. 2011; Cai et al. 2017; Babish et al. 2016),
one trial involved subjects with isolated hypercholesterol-
emia (Toth et al. 2015), one trial recruited participants with
previous ischemic heart disease (Campolongo et al. 2016),
two similar trials recruited subjects under second-generation
antipsychotics (SGA) treatment (Bruno, Pandolfo, Crucitti,
Cacciola, et al. 2017; Bruno, Pandolfo, Crucitti, Maisano,
et al. 2017), and one trial included women with breast can-
cer and receiving aromatase inhibitors treatment (Izzo et al.
2017). Five studies had a single-arm intervention, while six
of them showed double or multiple-arm designs by compar-
ing different doses of bergamot, using a placebo or statin
group as comparison arm. It is important to point out that
one trial referred to have a randomized clinical trial design
by comparing bergamot effect with placebo; however,
authors did not report placebo group results and they only
reached conclusions using changes in lipid profile after the
intake of bergamot supplements (Gliozzi et al. 2014).
Dietary intervention duration ranged from 1month to
6months and bergamot doses used in the different studies
ranged from 150mg/day in the study by Toth et al. (2015)
to 1500mg as the maximum dose in the study carried out
by Mollace et al. (2011)
Quality of the studies
The overall quality score of the included studies is summar-
ized in Table 1 and ranged from 0.27 to 0.96, with a mean
score of 0.55. Detailed description of each issue assessment
for each study is included in Supplemental Table 1. The
greatest concerning issues were randomization of descrip-
tions, blinding of investigators and subjects, sample size cal-
culation, appropriate analytic methodology, and controlling
for confounding factors. Among six studies including a
randomized clinical trial design, only two described random-
ization process and carried out a blinded intervention.
Among 12 included trials, only one included a sample size
calculation and two of them partially described it. In
Figure 1. Flow chart of the study selection.
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addition, eight of them did not use an appropriate statistical
analysis or it was partially suitable and only one study made
a statistical analysis taking into account the confounding
factors; this is one of the main reasons why conclusions of
most of the studies have been considered as partially or
completely not supported by the results.
Change on lipid profile
Among five studies that administrated 500mg of bergamot,
four of them used bergamot as an isolated component and
one of them used bergamot as part of a complex nutraceut-
ical including soy, phytosterols or berberine, among others.
Four out of five studies found a significant effect of berga-
mot on lipid profile while one of them did not describe sig-
nificant differences after the intervention. This study was
carried out by Bruno, Pandolfo, Crucitti, Cacciola, et al.
(2017) who recruited 28 subjects under SGAs treatment
receiving 500mg/day of Bergamot-derived polyphenolic frac-
tion (BPF) during 30 days. In contrast, Mollace et al. (2011)
randomized 237 participants with combined hyperlipidemia
to 500, 1000mg/day of bergamot or placebo during 30 days,
69 subjects taking 500mg/day of BPF obtained significant
reductions of total cholesterol, LDL cholesterol and
triglycerides with respect to the placebo group
(–21.8 ± 1.40%, –24.1 ± 1.5%, –30.5 ± 3.2%, respectively). On
the other hand, Dahlberg et al. (2017) randomized 32 sub-
jects with overweight or obesity and at least two cardiovas-
cular risk factors in two groups: a low glycemic load
Mediterranean diet and the same intervention plus a nutra-
ceutical including 500mg/day of bergamot fruit extract, soy,
berberine, and phytosterols, among other components.
Authors found significant differences between baseline and
final values in lipid profile in both study groups, although
the change was greater in participants receiving the nutra-
ceutical, who showed decreases of 17.3%, 18.8%, and 50.8%
in total cholesterol, LDL cholesterol and triglycerides,
respectively (Dahlberg et al. 2017). Cai et al. (2017) random-
ized 98 subjects with mixed hyperlipidemia to receive either
a nutraceutical supplementation including 500mg/day of
bergamot extract, among others, or placebo for 84 days.
They just found significant decreases in LDL cholesterol
(7.63%) what was statistically significant compared to the
placebo group (p¼ 0.032). Finally, Babish et al. (2016)
recruited 11 subjects with moderate hypercholesterolemia
who were supplemented with 500mg of BPF and 200mg of
phytocomplex mixture each day. Participants showed signifi-
cant decreases in total cholesterol (12.3%) and LDL choles-
terol (15.4%) but not in triglycerides concentration. Subjects
Figure 2. The effect of bergamot on lipid profile according to the type of bergamot component that was administered.
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with a baseline concentration of glycated hemoglobin
(HbA1c) > 5.4%, HOMA-IR score > 2 or elevated triglycer-
ides showed greater reductions in their lipid profile, espe-
cially in their triglyceride levels (Table 1).
Three studies used doses below 500mg of bergamot
extract, of which two used bergamot as part of a complex
nutraceutical and one of them used bergamot as isolated
active principle. All of them found statistically significant
decreases both in total cholesterol, LDL cholesterol and tri-
glycerides. Di Folco et al. (2018) recruited 80 subjects with
overweight and metabolic syndrome, who were randomized
to a low-calorie Mediterranean diet (control group) or the
same intervention plus 200mg/day of a dry extract of berga-
mot juice with 120mg of phytosterols. Only the intervention
group (supplemented with 200mg/day of bergamot) showed
significant reductions in total cholesterol (15.2%), LDL chol-
esterol (22.1%) and triglycerides (11.5%) concentration with
respect to the baseline. Campolongo et al. (2016) random-
ized 64 subjects with previous ischemic heart disease in two
groups: one of them was treated with 40mg of simvastatin,
and another group was treated with 20mg of simvastatin
plus nutraceutical including 400mg/day of bergamot, phy-
tosterols, artichoke and vitamin C. Both groups showed sig-
nificant reductions in lipid profile suggesting an additive
effect when adding the nutraceutical to lower doses of sim-
vastatin. Finally, in a study conducted by Toth et al. (2015),
80 patients with hypercholesterolemia received 150mg/day
of flavonoids coming from bergamot during 180 days.
Authors described similar reductions in total cholesterol
(13.2%), LDL cholesterol (18.2%) and triglycerides (16.5%)
than those reported by Di Folco et al. (2018) and
Campolongo et al. (2016).
Three studies administered 1000mg of bergamot as iso-
lated principle active. Two of them found statistically signifi-
cant improvement in lipid profile while one of them did
not. This study was carried out by Bruno, Pandolfo,
Crucitti, Maisano, et al. (2017) who prescribed 1000mg/day
of BPF for 30 days to 15 subjects under SGA treatment. In
contrast, Gliozzi et al. (2013) showed that subjects with
mixed hyperlipidemia receiving 1000mg/day of BPF had
similar reductions in total cholesterol (31.3%), LDL choles-
terol (40.8%), and triglycerides (30.7%) than subjects under
treatment with 10mg/day of rosuvastatin. They also proved
that participants treated with 1000mg/day of BPF plus
10mg of rosuvastatin showed the same improvement in
lipid profile than subjects receiving 20mg/day of rosuvasta-
tin. This synergistic or additive effect was also described by
Campolongo et al. who described a similar decrease in total
cholesterol, LDL cholesterol and triglycerides in those partic-
ipants receiving simvastatin 20mg plus 400mg/day (as part
of a complex nutraceutical) than those taking simvastatin
40mg. Finally, in previously described study carried out by
Mollace et al. (2011), dyslipidemic participants taking
1000mg/day of BPF had greater significant reductions in
LDL cholesterol than those receiving 500mg/day
(–36.0 ± 1.4% vs. –24.1 ± 1.5%, respectively) or pla-
cebo group.
Only two studies used a dose of bergamot higher than
1000mg/day and both found a significant effect of bergamot
on lipid profile. Gliozzi et al. (2014) prescribed 1300mg/day
of BPF to 107 patients with nonalcoholic fatty liver disease
and metabolic syndrome for 120 days. The intervention led
to significant decreases in total cholesterol (25.7%), LDL
cholesterol (37.7%) and triglycerides (31.0%). However, it is
important to point out that results of placebo group are not
included in the manuscript that may be essential to reach
definitive conclusions according to study design. Finally, 32
subjects with mixed hyperlipidemia received 1500mg of ber-
gamot combined with hypocaloric diet (1600 kcal/day). This
study reported that the reduction of total cholesterol and
LDL cholesterol was lower in patients treated with 1000mg
of bergamot, although it was only a statistically significant
reduction compared to the control-placebo group (Mollace
et al. 2011).
It should be noted that one of the found articles did not
explicitly indicate the bergamot dose used in the interven-
tion. This study was conducted by Izzo et al. (2017) who
recruited 41 women with breast cancer who were prescribed
with a nutraceutical composed of bergamot, phytosterol and
vitamins. Authors found significant reductions in total chol-
esterol, LDL cholesterol and triglycerides with respect to
the baseline.
Figure 2 shows the effect of bergamot on lipid profile
based on the type of component that was administered (A)
BPF or (B) any component of bergamot including BPF,
compared to placebo or diet intervention. Mean changes in
each lipid parameter for every study were used to figure out
the graphics. The figure shows a dose-dependent effect of
bergamot with higher decreasing in total cholesterol, LDL
cholesterol and triglycerides concentration when they
received higher doses of BPF or with any other form
of bergamot.
Among 12 studies included in the systematic review,
eight trials reported significant increased effect in HDL chol-
esterol concentration after receiving bergamot in any form.
The study carried out by Cai et al. (2017) did not find statis-
tically significant differences. Even though, it is important to
note that Babish et al. (2016), Bruno, Pandolfo, Crucitti,
Cacciola, et al. (2017) and Dahlberg et al. (2017) showed
light although significant decreases in HDL cholesterol con-
centration, that ranged from 1% to 6.5%.
Discussion
To our knowledge, this is the first systematic review aiming
to explore the effect of bergamot in lipid profile in humans.
We found 12 studies of which: 9 showed significant decrease
of total cholesterol, triglycerides and LDL cholesterol; 1 only
showed significant decrease in LDL cholesterol; and 2 did
not find significant change in any lipid variable. Eight trials
reported HDL cholesterol increase after intervention with
bergamot in any form, while three studies described slight
but significant decreases in HDL cholesterol concentration.
A dose-dependent effect can be deduced from the studies
but it should be confirmed with larger trials. However, it is
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essential to point out that studies had quite heterogenous
designs and scientific quality of the studies was quite lim-
ited. The first issue is crucial to reach conclusions since ber-
gamot was provided in different forms: (a) isolated
phytosterols of bergamot; (b) dry extract of whole bergamot
juice; and (c) as part of a complex nutraceutical including
other substances like phytosterols, artichoke or vitamin C.
Thus, a solidly elucidation of whether bergamot has a sig-
nificant effect on lipid profile in humans, which would be
the optimal dose, and the mechanism responsible for this
benefit, should still be clarified.
Statins are the main therapeutic approach in dyslipidemia
management due to their solidly demonstrated cholesterol
decreasing and cardiovascular protective effect (Stone et al.
2014; Baigent et al. 2005). However, some subjects show sta-
tin-intolerance especially at high doses (Rosenson et al.
2017; Serban et al. 2017). Inadequate lipid-lowering therapy
and nonadherence to statin treatment are the main causes of
failing to achieve LDL cholesterol targets (Guglielmi et al.
2017). Nutraceuticals can help to achieve lipid therapeutic
goals and reduce cardiovascular residual risk. However, data
about them are still limited. A recent position paper of
International Lipid Expert Panel established that nutraceuti-
cals could reach an LDL cholesterol reduction from <10%
to 20%, although some of them or the combinations of dif-
ferent nutraceuticals could achieve greater reductions in
LDL cholesterol(Banach et al. 2018). Our systematic review
founded 12 trials exploring the effect of bergamot effect on
lipid profile in humans; among them, 9 trials showed signifi-
cant improvement in lipid parameters. The decrease in total
cholesterol varied from 12.3% to 31.3%, from 7.63% to
40.8% in LDL cholesterol and from 11.5% to 39.5% in trigly-
cerides. These improvements are similar to those reported
when taking red yeast rice (15–25% decrease in LDL choles-
terol), phytosterols (8–12%) or berberine (15–20%), among
others (Banach et al. 2018).
A dose-response effect could be deducted from the stud-
ies we have analyzed. Overall, higher decreases in total chol-
esterol, LDL cholesterol, and triglycerides were observed
with higher bergamot doses when mean changes were calcu-
lated including the results of all trials (Figure 2). Although
we found a linear association between bergamot dose and
lipid profile improvement, there is a high variation in the
lipid profile reduction within these studies. In this way, Cai
et al. (2017) reported a decrease in LDL cholesterol of 7.63%
when taking 500mg/day dose of bergamot, while the same
dose led to a decrease of 24.1% in the trial conducted by
Mollace et al. (2011) On the other hand, the study carried
out by Toth et al. (2015) included a low dose of 150mg/day
of flavonoids coming from bergamot and they found a
18.2% decrease in LDL cholesterol. Based on the other trials,
a lower effect would had been expected if a linear dose-
response would had existed. It is crucial to note that partici-
pants characteristics are quite different among trials and,
most importantly, it results quite heterogeneous the way in
which bergamot was administered. This could play an essen-
tial role in the findings observed. While Cai et al. (2017)
studied the effect of a whole-bergamot extract (within a
complex nutraceutical), Mollace et al. (2011) used BPF and
Toth et al. (2015) provided isolated bergamot flavonoids.
Animal and in vitro studies suggested that polyphenols, par-
ticularly, flavonoids, such as melitidin and brutieridinin
combination with other flavonoid glycosides present in ber-
gamot, are likely to be responsible for lipid-lowering effects
of this fruit (Di Donna et al. 2014; Choe et al. 2001; Miceli
et al. 2007). Thus, it would be vital to solidly establish which
is the most effective way (in terms of lipid-lowering effect)
of bergamot supplementation in humans including either
isolation of certain flavonoids, whole polyphenols extraction
or whole bergamot juice extract. Future studies should also
focus on determining the exact dose that would reach the
maximum benefit on lipid metabolism with no side effects
and whether the effects could reach a plateau at a cer-
tain dose.
One of the main observations obtained of this systematic
review is that adding bergamot to low-doses of statins led to
a similar lipid profile improvement than could be reached
with higher doses, suggesting a synergic effect between sta-
tins and bergamot. Despite findings are promising, only two
studies included small sample number have explored this
issue. Gliozzi et al. (2013) demonstrated that adding BPF to
rosuvastatin 10mg showed the same reduction in lipid
parameters than the improvement achieved under rosuvasta-
tin 20mg treatment. Similar results were reported by
Campolongo et al. (2016) who observed an equivalent
reduction in LDL cholesterol when adding bergamot to sim-
vastatin 20mg with respect to those who received simvasta-
tin 40mg. High-risk or very-high-risk patients with partial
statin intolerance (who can tolerate a dose of statin that is
less than required based on their cardiovascular risk) could
be benefited by this therapeutic option (Banach et al. 2018).
Bergamot contains flavanones (including brutieridin, meliti-
din and HMG-neoeriocitrin) which have been demonstrated
to inhibit 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase like statins (Di Donna et al. 2014). Some
authors have also proposed different mechanisms that may
concur in lipid homeostasis regulation by flavonoids. These
included the activation of situin-1, which in turns activate
adenosine monophosphate-activated protein kinase
(AMPK)-a by increasing fatty acid oxidation and decreasing
VLDL synthesis through of hepatocyte nuclear factor 4
(HNF4) inhibition, sterol regulatory element-binding protein
1 (SREBP-1) regulation (Tsutsumi et al. 2014; Bruckbauer
and Zemel 2014; Chang et al. 2013; Quesada et al. 2009)
and the inhibition of the pancreatic cholesterol ester hydro-
lase and Acyl-CoA cholesterol acyltransferase, which
increase the cholesterol fecal excretion (Musolino et al.
2017). Despite this is the most probable mechanism like ber-
gamot, there are other mechanisms that have been proposed
to be responsible for lipid-lowering effects of bergamot.
Other potential mechanisms include increased gene tran-
scription and increased membrane translocation of the LDL
receptor, which could be mediated by proliferator-activated
receptors gamma (PPAR-c) activation (Farras et al. 2013;
Kumar et al. 1997). Although any study has specifically
explored the effect of bergamot alone by comparing to its
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combination with other nutraceutical components, a syner-
gic effect of lipid-lowering nutraceuticals is deducted from
published research. Those studies using low doses of berma-
got together to other bioactive components have reached
similar decreases than those using higher doses of bergamot
alone. These findings point out a similar synergistic effect
than the one described with statins by influencing on differ-
ent lipid metabolic pathways.
It is essential to emphasized that quality assessment of
trials revealed important issues which limit interpretation
and conclusions that can be reached based on these trials.
Among 12 studies identified through a systematic review
process, only half of them used a randomization design and
only two trials described how the randomization process
was carried out. Most importantly, only one study took into
consideration confounding factors in analyzing study data.
Adjustment of lipid parameters change after intervention
with bergamot by body weight or dietary changes, among
others, is crucial to correct interpretation of results and
establish firm conclusions. According to the study design,
many trials carried out some statistical approaches that
could be inappropriate according to study design. Limited
methodology quality of trials is a cornerstone to establish
definitive conclusions that should be considered when inter-
preting the results.
In conclusion, this is the first systematic review aiming to
compile all studies that have explored the effect of bergamot
on lipid profile in humans. Nine of 12 founded trials
showed a significant decrease in total cholesterol, triglycer-
ides and LDL cholesterol, while one study showed a signifi-
cant decrease just in LDL cholesterol. Two trials did not
find significant change in any variable. Eight trials reported
HDL increase after intervention with bergamot in any form.
Overall, a dose-dependent effect and a potential synergistic
effect when administering with statins can be deducted from
these trials. Possible synergistic effect could be explained
because the mechanism of bergamot acts to different levels:
inhibiting the HMG-CoA reductase, the pancreatic choles-
terol ester hydrolase and Acyl-CoA cholesterol acyltransfer-
ase, which would produce lower cholesterol synthesis and
higher cholesterol fecal excretion. Promising findings give
away from an alternative therapeutic option in dyslipidemia
management with bergamot supplementation, especially in
patients with moderate hypercholesterolemia, low cardiovas-
cular risk or intolerant to traditional pharmacological treat-
ment. However, crucial issues are still remained to be
clarified before a solid recommendation on this nutraceutical
could be performed. These questions include the form in
which most efficiently bergamot should be provided (BPF,
certain flavonoids or whole bergamot juice extraction) and
the optimal dose and its safety.
Supplementary information
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publisher’s website at [article DOI].
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